birb 796 bs + pantoprazole

BIRB 796 BS + pantoprazole is a combination of two pharmaceutical agents: **BIRB 796 BS (doramapimod)**, a small molecule inhibitor targeting the p38 mitogen-activated protein kinase (p38MAPK), and **pantoprazole**, a proton pump inhibitor for gastric acid suppression. BIRB 796 BS acts by binding to the allosteric site of p38MAPK and inhibits its phosphorylation, leading to reduced production of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-8, and exhibits anti-inflammatory and antitumor activities. It has been evaluated for chronic inflammatory diseases, rheumatoid arthritis, psoriasis, Crohn's disease, and some neoplasms[1][3][4][5]. Pantoprazole is widely used for the treatment of gastroesophageal reflux disease and for gastric acid suppression during combination therapies. The rationale for combining BIRB 796 BS with pantoprazole may be to reduce gastrointestinal side effects of anti-inflammatory therapy or for use in settings where both inflammation and acid suppression are required, although this particular combination is not a standard labeled formulation.

Other names

doramapimodBIRB 796 BS + pantoprazole